Top Line Performance Decline: Kenvue reported a 4.2% decline in organic sales for Q2 2025, which was below expectations. The sales drop was attributed to soft seasonal demand in allergy and sun care categories, particularly in the U.S. market, and a disconnect between consumer consumption trends and sales performance. Global consumption grew year-over-year, indicating potential for brand improvement despite sales challenges.

Revised 2025 Outlook: The company has revised its its guidance for 2025, now expecting organic sales to decline in the low single digits. Operating margins are projected to contract due to strategic price investments, fixed cost deleverage, and inflationary challenges, with an adjusted diluted EPS forecast range of $1.00 to $1.05.

Leadership Transition and Strategic Review: Kenvue is undergoing a leadership transition with Kirk Perry stepping in as interim CEO and Amit Banati as the new CFO. The Board has initiated a comprehensive review of strategic alternatives with the goal of optimizing the company's brand portfolio and unlocking shareholder value. Initial observations suggest a need to streamline operations to reduce complexity.